Tumor-bearing mice were subsequently treated with anti-PD-L1 antibodies, blocking the inhibitory PD-1/PD-L1 pathway, and with agonistic antibodies targeting the costimulatory receptor OX40 (Figure 1A). This evidence concerns the gene TNFRSF4 and neoplasm.